12/2
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/2
06:16 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
11/29
01:34 am
ird
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
Medium
Report
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
11/26
06:43 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/25
06:11 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
11/20
08:36 am
ird
Opus Genetics to Participate in Upcoming Investment Conferences [Yahoo! Finance]
Low
Report
Opus Genetics to Participate in Upcoming Investment Conferences [Yahoo! Finance]
11/20
08:00 am
ird
Opus Genetics to Participate in Upcoming Investment Conferences
Medium
Report
Opus Genetics to Participate in Upcoming Investment Conferences
11/13
07:07 pm
ird
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease [Yahoo! Finance]
Low
Report
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease [Yahoo! Finance]
11/13
08:46 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
11/13
07:00 am
ird
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Medium
Report
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
11/12
08:19 am
ird
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line [Seeking Alpha]
Low
Report
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line [Seeking Alpha]
11/12
07:00 am
ird
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Low
Report
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
11/7
10:27 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
11/6
07:00 am
ird
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Low
Report
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
11/6
07:00 am
ird
Opus Genetics Announces $23 Million Registered Direct Offering
Low
Report
Opus Genetics Announces $23 Million Registered Direct Offering
11/4
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/3
08:00 am
ird
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
Medium
Report
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
11/1
08:33 am
ird
With Opus Genetics Up 16%, Insider Buyers Count Their Returns [Yahoo! Finance]
Medium
Report
With Opus Genetics Up 16%, Insider Buyers Count Their Returns [Yahoo! Finance]
10/29
07:17 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Wedbush. They set an "outperform" rating and a $8.00 price target on the stock.
Low
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Wedbush. They set an "outperform" rating and a $8.00 price target on the stock.
10/16
08:05 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $9.00 price target on the stock.
Low
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $9.00 price target on the stock.
10/14
08:39 am
ird
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference [Yahoo! Finance]
Low
Report
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference [Yahoo! Finance]
10/14
08:00 am
ird
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Low
Report
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
10/2
08:05 am
ird
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 [Yahoo! Finance]
Low
Report
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 [Yahoo! Finance]
10/2
08:00 am
ird
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Neutral
Report
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
9/30
08:13 am
ird
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) [Yahoo! Finance]
High
Report
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) [Yahoo! Finance]